CBMX: CombiMatrix Corporation - Summary | Jitta

CombiMatrix Corporation

NASDAQ:CBMX

Notice
Stock data is unavailable or the company’s delisted.
Price
$6.00
Loss Chance
58.4%
1.80JITTA SCORE
> 1,000%Under Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (28)
Recent Business Performance (50)
Financial Strength (10)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Revenue and EarningEarning loss detected in 2016
Operating MarginDeclined
Recent Business PerformanceEarning decline 36.91% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.80
> 1,000%
COMPANY DESCRIPTION
As of November 14, 2017, CombiMatrix Corporation was acquired by Invitae Corporation. CombiMatrix Corporation provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company’s testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. It serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California. As of November 14, 2017, CombiMatrix Corporation operates as a subsidiary of Invitae Corporation.